ArticleDiscover oncology2025
LMNB1 regulates breast cancer cell senescence and migration through PPAR signaling pathway.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- CancerSubtypeXplore: A Modular Platform for Multiomics Cancer Subtype Prediction and Biomarker Consensus Discovery.Computational and structural biotechnology journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is the malignant tumor with the highest incidence in the world. LMNB1 is an important component of the nuclear backbone. LMNB1 is abnormally highly expressed in breast cancer, but its role in tumors still needs to be comprehensively studied. In this study, we overexpress and knockdown LMNB1 in breast cancer cells and explore the effects of LMNB1 on cell proliferation, senescence, migration, and underlying mechanisms. We analyzed the expression level of LMNB1 in breast cancer and its clinical relevance utilizing bioinformatics methods, qRT-PCR, and western blot. To elucidate the effects and mechanisms of LMNB1 on breast cancer cells, we performed SA-β-gal staining, CCK-8, colony formation, wound healing, and Transwell assays in breast cancer cells with LMNB1 overexpression and knockdown, and then examined the expression of relevant genes and proteins. In addition, we also analyzed the signaling pathways regulated by LMNB1 with the help of bioinformatics tools. Overexpression of LMNB1 significantly inhibited the senescence of cancer cells and promoted cell proliferation, migration, and invasion. The opposite results were obtained in LMNB1 knockdown cells. LMNB1 inhibited the PPAR signaling pathway in breast cancer. Our study suggests that LMNB1 is a novel therapeutic target in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.